Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986517 · 1 trial · 1 indication
For part 1 only
| Arm | Type | Description |
|---|---|---|
| Part 1A Monotherapy Dose Escalation | EXPERIMENTAL | - |
| Part 1B Combination Dose Escalation | EXPERIMENTAL | - |
| Part 1C: Monotherapy PD Sub-study | EXPERIMENTAL | - |
| Part 2A: Monotherapy Dose Expansion Cohort A | EXPERIMENTAL | - |
| Part 2A: Monotherapy Dose Expansion Cohort B | EXPERIMENTAL | - |
| Part 2A: Monotherapy Dose Expansion Cohort C | EXPERIMENTAL | - |
| Part 2B: Combination Dose Expansion Cohort A | EXPERIMENTAL | - |
| Part 2B: Combination Dose Expansion Cohort B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986517 | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have an ECOG performance status of 0 to 1. * Participants must have measurable disease by RECIST v1.1 (radiologically measured by the Investigator). * Participants must have documented histologically or cytologically confirmed advanced, unresectable/metastatic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986517 is an investigational small molecule being developed by Bristol-Myers Squibb for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved for any indication. The compound is being evaluated as a first-in-human therapy in a biomarker-selected patient population.
BMS-986517 is being studied for use in patients with advanced solid tumors. It is an investigational agent in Phase 1 development and is not approved for any cancer treatment. The ongoing trial enrolls adults with advanced solid tumors across multiple countries, including the United States, China, Denmark, Japan, and Spain.
BMS-986517 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is the sponsor of the ongoing Phase 1/2a clinical trial evaluating the compound in advanced solid tumors.
BMS-986517 is in Phase 1 clinical development. A Phase 1/2a first-in-human study is currently recruiting participants with advanced solid tumors. The drug is investigational and has not received FDA approval or any regulatory approval for commercial use.
BMS-986517 is being evaluated in one active clinical trial, NCT07160725, titled A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors. The trial is currently recruiting, with an estimated enrollment of 540 participants across the United States, China, Denmark, Japan, and Spain.